Corrigendum to “Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight” [Neurobiol. Aging 33 (2012) 831.e21–831.e31](S0197458011002995)(10.1016/j.neurobiolaging.2011.07.014);Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: Structural insight

Neurobiology of Aging

Volumn 33, Issue 4, 2012, Pages 831.e21-831.e31

  Amtul, Zareen ^a,b   Uhrig, Markus ^a   Wang, Lin ^b,c   Rozmahel, Richard F ^b,c   Beyreuther, Konrad ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; Arachidonic acid; COS 7 cells; Structural template; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANANDAMIDE; ARACHIDONIC ACID; GAMMA SECRETASE; LEUKOTRIENE B4; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTEIN INHIBITOR; SESAMIN; THROMBOXANE; THROMBOXANE B2;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL STRAIN COS7; CONTROLLED STUDY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD COMPOSITION; FOOD INTAKE; GENETIC TRANSFECTION; IMMUNOBLOTTING; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSGENIC MOUSE;

EID: 84856950778     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2017.12.007     Document Type: Erratum

References (47)

1. Akisu M., Huseyinov A., Baka M., Yalaz M., Kultursay N. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the generation of platelet-activating factor and leukotriene B4 in hypoxic-ischemic brain in young mice. Prostaglandins Leukot. Essent. Fatty Acids 2002, 67:429-433.
2. Amtul Z., Uhrig M., Rozmahel R.F., Beyreuther K. Structural insight into the differential effects of omega-3 and omega-6 fatty acids on the production of Abeta peptides and amyloid plaques. J. Biol. Chem 2011, 286:6100-6107.
3. Amtul Z., Uhrig M., Supino R., Beyreuther K. Phospholipids and a phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and amyloid-beta 42/40 ratios. Neurosci. Lett 2010, 481:73-77.
4. Amtul Z., Westaway D., Cechetto D.F., Rozmahel R.F. Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer's disease. Brain Pathol 2011, 21:321-329.
5. Amtul Z., Keet M., Wang L., Westaway D., Merrifield P., Rozmahel R.F. DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: Is it time to evaluate composite lipid diet? 2011, PLoS ONE PONE-D-11-09286R1 10.1371/journal.pone.0024094.
6. Bazan N.G., Colangelo V., Lukiw W.J. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 2002, 68-69. 197-210.
7. Bazan N.G., Rodriguez de Turco E.B., Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J. Neurotrauma 1995, 12:791-814.
8. Bordayo E.Z., Fawcett J.R., Lagalwar S., Svitak A.L., Frey W.H. Inhibition of ligand binding to G protein-coupled receptors by arachidonic acid. J. Mol. Neurosci 2005, 27:185-194.
9. Chalimoniuk M., Stolecka A., Cakała M., Hauptmann S., Schulz K., Lipka U., Leuner K., Eckert A., Muller W.E., Strosznajder J.B. Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells. Acta Biochim. Pol 2007, 54:611-623.
10. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein. J. Biol. Chem 2001, 276:21562-21570. 695.
11. Christie M.J., Vaughan C.W., Ingram S.L. Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism. Inflamm. Res 1999, 48:1-4.
12. Colin A., Reggers J., Castronovo V., Ansseau M. Lipids, depression and suicide. Encephale 2003, 29:49-58.
13. Dupret D., Revest J.M., Koehl M., Ichas F., De Giorgi F., Costet P., Abrous D.N., Piazza P.V. Spatial relational memory requires hippocampal adult neurogenesis. PLoS One 2008, 3:e1959.
14. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
15. Esposito G., Giovacchini G., Liow J.S., Bhattacharjee A.K., Greenstein D., Schapiro M., Hallett M., Herscovitch P., Eckelman W.C., Carson R.E., Rapoport S.I. Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J. Nucl. Med 2008, 49:1414-1421.
16. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2007, Elsevier Academic Press, San Diego. 3rd Edn.
17. Gallai V., Sarchielli P., Trequattrini A., Franceschini M., Floridi A., Firenze C., Alberti A., Di Benedetto D., Stragliotto E. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J. Neuroimmunol 1995, 56:143-153.
18. Holland B., Welch A.A., Unwin I.D., Buss D.H., Paul A.A., Southgate D.A.T. McCance and Widdowson's the Composition of Foods 1991, Royal Society of Chemistry and Ministry of Agriculture, Fisheries, and Food, Cambridge, UK.
19. Hoshino T., Nakaya T., Homan T., Tanaka K., Sugimoto Y., Araki W., Narita M., Narumiya S., Suzuki T., Mizushima T. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J. Biol. Chem 2007, 282:32676-32688.
20. Ida N., Hartmann T., Pantel J., Schröder J., Zerfass R., Förstl H., Sandbrink R., Masters C.L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem 1996, 271:22908-22914.
21. Jensen M., Hartmann T., Engvall B., Wang R., Uljon S.N., Sennvik K., Näslund J., Muehlhauser F., Nordstedt C., Beyreuther K., Lannfelt L. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med 2000, 6:291-302.
22. Kjome J.R., Swenson K.A., Johnson M.N., Bordayo E.Z., Anderson L.E., Klevan L.C., Fraticelli A.I., Aldrich S.L., Fawcett J.R., Venters H.D., Ala T.A., Frey W.H. Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. J. Mol. Neurosci 1998, 10:209-217.
23. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
24. Lichtenthaler S.F., Beher D., Grimm H.S., Wang R., Shearman M.S., Masters C.L., Beyreuther K. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1365-1370.
25. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4245-4249.
26. Matsumoto Y., Yamaguchi T., Watanabe S., Yamamoto T. Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology 2004, 46:1195-1200.
27. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
28. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol 1999, 46:860-866.
29. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys 1993, 301:41-52.
30. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Wilson R.S. Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 2004, 62:1573-1579.
31. Obukowicz M.G., Raz A., Pyla P.D., Rico J.G., Wendling J.M., Needleman P. Identification and characterization of a novel delta6/delta5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. Biochem. Pharmacol 1998, 55:1045-1058.
32. Ogawa Y., Calhoun W.J. The role of leukotrienes in airway inflammation. J. Allergy Clin. Immunol 2006, 118:789-798.
33. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lütjohann D., Hartmann T., Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis 2006, 23:563-572.
34. Palmer C. Hypoxic-ischemic encephalopathy. Therapeutic approaches against microvascular injury, and role of neutrophils, PAF, and free radicals. Clin. Perinatol 1995, 22:481-517.
35. Piomelli D. Eicosanoids in synaptic transmission. Crit. Rev. Neurobiol 1994, 8:65-83.
36. Piomelli D., Wang J.K., Sihra T.S., Nairn A.C., Czernik A.J., Greengard P. Inhibition of Ca2+/calmodulin-dependent protein kinase II by arachidonic acid and its metabolites. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:8550-8554.
37. Qin W., Ho L., Pompl P.N., Peng Y., Zhao Z., Xiang Z., Robakis N.K., Shioi J., Suh J., Pasinetti G.M. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem 2003, 278:50970-50977.
38. Rabinovich A.L., Ripatti P.O. On the conformational, physical properties and functions of polyunsaturated acyl chains. Biochim. Biophys. Acta 1991, 1085:53-62.
39. Rinne J.O., Laakso K., Lönnberg P., Mölsä P., Paljärvi L., Rinne J.K., Säkö E., Rinne U.K. Brain muscarinic receptors in senile dementia. Brain Res 1985, 336:19-25.
40. Sanchez-Mejia R.O., Newman J.W., Toh S., Yu G.Q., Zhou Y., Halabisky B., Cissé M., Scearce-Levie K., Cheng I.H., Gan L., Palop J.J., Bonventre J.V., Mucke L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci 2008, 11:1311-1318.
41. Saxe M.D., Malleret G., Vronskaya S., Mendez I., Garcia A.D., Sofroniew M.V., Kandel E.R., Hen R. Paradoxical influence of hippocampal neurogenesis on working memory. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4642-4646.
42. Shimizu S., Akimoto K., Shinmen Y., Kawashima H., Sugano M., Yamada H. Sesamin is a potent and specific inhibitor of delta 5 desaturase in polyunsaturated fatty acid biosynthesis. Lipids 1991, 26:512-516.
43. Srinivasan B.D., Kulkarni P.S. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog. Clin. Biol. Res 1989, 312:229-249.
44. St George-Hyslop P.H. Piecing together Alzheimer's. Sci. Am 2000, 283:76-83.
45. Tilley S.L., Coffman T.M., Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest 2001, 108:15-23.
46. Townsend K.P., Praticò D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005, 19:1592-1601.
47. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005, 28:202-208.